Tamsulosin Hydrochloride Capsule
Product Images NDC 63672-0021

7 FDA label images from Synthon B.v. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tamsulosin Hydrochloride (NDC 63672-0021). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Synthon B.v., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Tamsulosin Hydrochloride Capsules 1)

Chemical Structure (Tamsulosin Hydrochloride Capsules 1)
Chemical structure of tamsulosin hydrochloride, showing its molecular arrangement with identifiable groups including methoxy, sulfonamide, and hydrochloride.*
FDA Label Image

Figure 1 (Tamsulosin Hydrochloride Capsules 2)

Figure 1 (Tamsulosin Hydrochloride Capsules 2)
A line graph depicting plasma concentration (ng/mL) of tamsulosin hydrochloride capsules over time (hours) comparing fasted and fed states. The graph shows plasma levels peaking earlier and higher under fasted conditions, with both lines gradually declining over 36 hours.*
FDA Label Image

Figure 2a (Tamsulosin Hydrochloride Capsules 3)

Figure 2a (Tamsulosin Hydrochloride Capsules 3)
A line graph depicting the mean change over the duration of treatment in weeks for three groups: 0.8 mg, 0.4 mg, and placebo. The x-axis shows treatment duration from 0 to 13 weeks and LOCF, while the y-axis indicates the mean change. The 0.8 mg group shows the greatest decrease, followed by 0.4 mg, and then placebo with the least change.*
FDA Label Image

Figure 2b (Tamsulosin Hydrochloride Capsules 4)

Figure 2b (Tamsulosin Hydrochloride Capsules 4)
A line graph showing the mean change over the duration of treatment (in weeks) for tamsulosin hydrochloride at 0.4 mg and 0.8 mg doses compared to placebo. The x-axis represents treatment duration up to 13 weeks, and the y-axis shows mean change values. The graph includes data points and trend lines for each treatment group with sample sizes noted at intervals.*
FDA Label Image

Figure 3a (Tamsulosin Hydrochloride Capsules 5)

Figure 3a (Tamsulosin Hydrochloride Capsules 5)
A line graph showing mean change in mL/sec over treatment duration in weeks for Tamsulosin hydrochloride oral capsules at 0.4 mg and 0.8 mg doses compared to placebo. The x-axis represents weeks of treatment, and the y-axis shows mean change values. Data points and trends are plotted for each group across the study period.*
FDA Label Image

Figure 3b (Tamsulosin Hydrochloride Capsules 6)

Figure 3b (Tamsulosin Hydrochloride Capsules 6)
A line graph depicting the mean change in a variable measured in mL/sec over the duration of treatment in weeks. The graph compares three groups: 0.8 mg dosage, 0.4 mg dosage of the treatment, and a placebo group. The x-axis shows the treatment duration from 0 to 13 weeks, with an additional point for LOCF. The y-axis represents mean change values ranging from 0 to 3 mL/sec. Both treatment doses show a greater increase compared to placebo over time.*
FDA Label Image

Tamsulosin Hydrochloride Capsules Usp, 0.4 mg Bulk Drum Label Synthon Hispania S.l. (Tamsulosin Hydrochloride Capsules 7)

Tamsulosin Hydrochloride Capsules Usp, 0.4 mg Bulk Drum Label Synthon Hispania S.l. (Tamsulosin Hydrochloride Capsules 7)
Label for Tamsulosin Hydrochloride Capsules USP, 0.4 mg, oral capsules. The label indicates each capsule contains 0.4 mg of tamsulosin hydrochloride. It includes storage instructions, labeler Synthon Hispania S.L. in Barcelona, Spain, and a barcode with the NDC 63672-0021-9. The package quantity is 20,000 capsules and it is marked for processing or repackaging only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.